Beyond ADCs: Antibody-encapsulated drug for targeted cancer therapy Authors: Linrong Li, Armando Giuliano, Qiang Sun, Xiaojiang Cui, Yuan Yuan Published: 2026 ABSTRACT AbstractAntibody-drug conjugates (ADCs) have transformed cancer treatment by covalently linking the monoclonal antibody with cytotoxic payload, yet their clinical potential remains constrained by intrinsic limitations: heterogeneous drug-to-antibody ratios, linker instability, manufacturing complexity, and drug resistance. These challenges highlight the need for fundamentally different drug formulation and delivery platforms. Antibody-encapsulated drugs (AEDs) leverage the single protein encapsulation technology to enable one antibody to noncovalently encapsulate a predefined number of payload molecules. AEDs allow for a fixed drug-to-antibody ratio, mitigate premature drug release, simplify manufacturing, and expand the range of compatible payloads and protein molecules. Preclinical investigation of trastuzumab-encapsulated actinomycin D, a HER2-targeted AED, has demonstrated potent antitumor activity across cancer models with varying HER2 expression levels, alongside a favorable toxicity profile in animal models. The broader translational feasibility of the single protein encapsulation platform is further supported by ongoing clinical trials of albumin-encapsulated therapeutics. Together, these advances position AED as a promising next-generation targeted cancer therapy that complements and potentially extends beyond conventional ADCs, offering a compelling strategy to overcome existing resistance mechanisms and therapeutic limitations. Over the past decade, rapid development of antibody-drug conjugates (ADCs) has fundamentally changed the cancer treatment landscape. By covalently linking the monoclonal antibody with cytotoxic payload, ADCs have transformed cancer treatment across multiple malignancies, including breast cancer [1], lymphoma [2], and urothelial carcinoma [3]. The Food and Drug Administration approvals of landmark ADCs such as trastuzumab deruxtecan and sacituzumab govitecan have validated the premise that antibody-directed delivery of anticancer payloads can improve efficacy while reducing systemic exposure relative to conventional chemotherapy. Despite this progress, the full potential of ADCs is constrained by intrinsic limitations of the conjugation-based drug formulation and delivery platform [4]. Development of effective and safe ADCs relies on the right target, antibody design, linker technology, and payload. Because the modular components of ADCs interact both structurally and functionally, optimization is often nontrivial and may come at the expense of manufacturability or safety. At the core of many challenges lies the chemical conjugation platform itself. First, stochastic conjugation produces heterogeneous drug-to-antibody ratios (DARs), which compromise both therapeutic efficacy and dosing predictability. Non-stochastic conjugations, including amino-acid engineering, disulfide re-bridging, and enzymatic coupling, improve DAR control at the cost of additional engineering complexity, and may introduce immunogenicity concerns. Second, linker instability and premature payload release can lead to systemic exposure, contributing to typical chemotherapy-related toxicities such as myelosuppression, gastrointestinal toxicity, as well as interstitial lung disease. Systemic exposure can be difficult to predict, and off-target toxicity continues to be a major cause of dose limitation in clinical practice [5]. Third, manufacturing complexity represents a major bottleneck. Dependence on linker-compatible payloads constrains chemical innovation, and multistep conjugation processes further impede scalable and cost-effective production. Lastly, both intrinsic and acquired drug resistance remain significant barriers to the clinical efficacy of ADCs. Multiple resistance mechanisms have been reported, including tumor heterogeneity, downregulation or mutation of the target antigen, altered internalization, impaired lysosomal trafficking, upregulation of efflux transporters, as well as dysregulated downstream signaling pathways [6]. These challenges suggest that incremental refinement of ADCs alone may not be sufficient to meet the growing clinical demand for safer and more predictable targeted therapies, underscoring the need for a fundamentally different drug formulation and delivery platform. As the field of drug delivery continues to advance, a broad spectrum of state-of-the-art controlled-release strategies — including liposomal formulations, polymeric nanoparticles, and protein nanocages — have been developed and clinically validated. The antibody-encapsulated drug (AED) offers such an alternative within this landscape. By leveraging single protein encapsulation (SPE) technology, AEDs enable one antibody to noncovalently encapsulate a predefined number of payload molecules, such that the antibody itself functions as a molecular container rather than a scaffold for conjugation (Fig. 1). Unlike ADCs, which are hampered by heterogeneous DARs, linker instability, manufacturing complexity, and multifactorial drug resistance, linker-free AEDs offer an encapsulation-based alternative that ensures a fixed DAR, circumvents linker-related payload release challenges, streamlines manufacturing, and broadens the range of compatible payloads and protein molecules. Schematic comparison of antibody-drug conjugate and antibody-encapsulated drug. From clinical and pharmaceutical perspectives, the following features of AED are particularly intriguing. First, AED does not involve chemical modification of the protein or payload, thus retaining the full function of both molecules. DAR is fixed by design, which eliminates heterogeneity and improves predictability of exposure for optimizing dosing. Second, because payloads are physically encapsulated within the antibody rather than covalently linked, issues related to linker instability and premature payload release are theoretically mitigated. This may reduce off-target toxicity and enhance drug efficacy in the tumor microenvironment. Third, SPE can simplify manufacturing and expand the range of compatible payloads and protein molecules, including highly insoluble or unlinkable molecules that are otherwise challenging to ADC platforms. SPE enables delivery of diverse payload classes, including high-potency cytotoxics (microtubule inhibitors, topoisomerase I inhibitors, and DNA-damaging agents), with potential extension to antiviral, antimicrobial, immune-modulatory, radio-therapeutic agents and multi-payload applications. Because AEDs may employ payloads and mechanisms distinct from those of ADCs, they could provide therapeutic opportunities in selected tumors that have acquired resistance to prior ADC therapies. Importantly, AEDs have now entered preclinical investigation, exemplified by trastuzumab-encapsulated actinomycin D (Tr-ACT2)—a HER2-targeted AED in which each antibody encapsulates two ACT molecules [7,8]. Tr-ACT2 demonstrated potent cytotoxic activities in vitro and in vivo in breast and lung cancer models. Preclinical data indicates that AEDs potently induce apoptosis, suppress survival signaling pathways, and inhibit tumor growth across models with markedly different target expression levels – features that may be clinically advantageous in tumors with heterogeneous antigen expression. In lung cancer xenograft model, Tr-ACT2 produced robust antitumor activity, achieving 64.2% tumor growth inhibition by day 14 at 1.0 mg/kg, compared with 23.7% for irinotecan at 50 mg/kg in parallel. Although ACT was often associated with severe off-target toxicities, Tr-ACT2 exhibited a favorable toxicity profile in animal models. Normalized body weight changes indicated that Tr-ACT2 at its MTD of 1.0 mg/kg, i.e., a dosage tenfold higher than the MTD of free ACT (0.1 mg/kg), showed a toxicity profile comparable to that of irinotecan at 50 mg/kg, suggesting an improved therapeutic index through payload encapsulation and targeted cellular uptake. Beyond AEDs, the translational feasibility of the SPE platform is further supported by the clinical advancement of albumin-encapsulated therapeutics. Notably, human serum albumin (HSA)-encapsulated doxorubicin is undergoing human phase Ib/IIa clinical trials (NCT07064018) in advanced cancers, and HSA-encapsulated SN38 (IND #: 164346) has been green-lighted by the FDA for colorectal cancer and other indications [9,10]. Together, these findings position AEDs as a next-generation antibody-based cancer therapy that complements and potentially extends beyond conventional ADCs, offering a powerful strategy to overcome existing therapeutic limitations for multidrug-resistant tumors. However, several technical challenges must be addressed before AEDs can advance toward clinical translation. First, the structural and physicochemical basis of noncovalent encapsulation remains to be rigorously elucidated using complementary structural and biophysical approaches, such as cryo-electron microscopy, molecular dynamics simulations, and quantitative binding analyses. Second, industrial-scale manufacturing of AEDs under regulatory standards has not been fully established, and standardized analytical methods for process validation and batch quality control are still needed. Third, current efficacy and safety data are largely derived from in vitro studies and rodent models; therefore, validation in more physiologically relevant preclinical systems is needed to comprehensively characterize pharmacokinetics, biodistribution, therapeutic efficacy, and toxicity profiles. Finally, the molecular mechanisms governing drug encapsulation, intracellular payload release, and antitumor activity remain incompletely understood and warrant further investigation. As targeted cancer therapeutics continue to evolve, design innovation will be critical for optimizing treatment outcomes. AED approach offers a novel targeted drug formulation and delivery platform with the potential to address the limitations of ADCs by expanding accessibility, improving safety, and enhancing efficacy. Overall, AED represents a promising direction for next-generation targeted cancer therapy, even at this early stage of development. Funding Dr. Xiaojiang Cui is funded by National Institutes of Health (2R01CA151610 and R21CA280458), Department of Defense (W81XWH-18-1-0067), Samuel Oschin Cancer Institute Research Development Fund, the Jim and Eleanor Department of Surgery Research Award, and Glazer Foundation Award. Footnotes CRediT authorship contribution statement Yuan Yuan: Conceptualization. Xiaojiang Cui: Conceptualization. Qiang Sun: Supervision. Armando Giuliano: Conceptualization. Linrong Li: Writing – original draft, Writing – review & editing. Ethics and Consent to Participate Not applicable. Declaration of Competing Interest The authors declare that they have no known competing interests. Contributor Information Linrong Li, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, USA; Department of Surgery, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Armando Giuliano, Department of Surgery, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Qiang Sun, Department of Breast Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. Xiaojiang Cui, Department of Surgery, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. Yuan Yuan, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA, USA. References